Web Alert: Biophan to Host Investor Conference Call Today at 10 a.m. Eastern; Senior Executives to Provide Updates on Product Development and Progress in Monetizing Intellectual Property Portfolio
Senior Biophan officers including Michael Weiner, CEO, and John Lanzafame, Vice President, Business Development, will discuss the Company's strategic initiatives and recent achievements. They will also take questions from investors.
The conference call will last approximately 30 minutes, and will be simultaneously webcast for listening via streaming audio. To participate in the call by phone or listen on the web, follow the instructions below. There is no charge.
WHAT: Biophan Technologies' Investor Conference Call. WHO: Michael Weiner, CEO, and John Lanzafame, Vice President, Business Development. WHEN: Today, October 24, at 10 a.m. Eastern. HOW: To connect to the conference call in the United States, please dial (800) 288-8967. International callers can dial (612) 332-0725. When prompted, please tell the operator that you would like to connect to the "Biophan Teleconference" call. This call is free of charge to all interested investors. WEB: To listen to the call on the Web via streaming audio, please visit http://www.trilogy-capital.com/biph_conference.html and follow the on-screen instructions. COST: The conference call is free of charge. ARCHIVE: The conference call will be archived for replay at http://www.trilogy-capital.com/biph_conference.html.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and image compatible with the magnetic resonance imaging (MRI) environment. The Company develops technologies that enable implanted medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and devices such as stents to be safely and effectively imaged under MRI. Biophan is developing these same technologies to provide new MRI contrast agents. Other applications include drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications. This total includes 42 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 106 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development and licensing agreements with Boston Scientific and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. Biophan is also listed on the Frankfurt Stock Exchange under the ticker symbol "BTN." For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.